I've read page 9 and 10, I don't see anything that we weren't aware of. Like any other prospectus, its full of "Risk Factor" disclaimers in case things do not work out. And at the worst case scenario, if they didn't get enough revenues in Q2 of 2020 - The company would simply resort to dilution.
Btw, From that same prospectus, the company does expect to achieve the 2 milestones.
Ancaster,
"The installation and commissioning is expected to be completed by the end of 2019 (delayed from the Company’s previous expectation of November 2019 in order to conserve available cash), while the licence amendment is expected to be received by the first week of February 2020."
Valleyfield,
"The Company must also finish installation of certain pieces of equipment and submit a
security package to Health Canada in respect of the remaining 22 rooms to expand the scope of the existing licence,
both of which are expected by the end of December 2019."
and here is a bit of good news from page 10...
"The Company previously announced that it had
identified savings opportunities for $4 million in annualized general administrative costs. Since that announcement,
the Company has identified further savings opportunities (primarily due to reduced professional and consulting fees
and head count reductions), resulting in additional projected savings of approximately $7.2 million on an annual basis. Taking these savings opportunities into account, the Company projects Canadian general and administrative expenses of $19.65 million for the 2020 fiscal year.
Fyi,
Ancaster alone will take them to cash flow positive.
